You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle

Alerts

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Checkpoint Blockade Therapy
579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address